StockNow
Calendar
Log in
U.S. Markets

BioNTech (BNTX) Q3 2026 (EUR): Revenue 1.29bln (exp. 1.03bln). Narrows its FY26 revenue guidance to 1.7-1.9bln (exp. 1.8bln, prev. 1.6-1.9bln)

ORIGINAL · NewsquawkBioNTech (BNTX) Q3 2026 (EUR): Revenue 1.29bln (exp. 1.03bln). Narrows its FY26 revenue guidance to 1.7-1.9bln (exp. 1.8bln, prev. 1.6-1.9bln)Read originalHide original

Future R&D costs under the collaboration with Roche (ROP SW) will be assigned to Roche.

StockNow breaking-news AI analysis

BioNTech reported Q3 revenue above the stated expectation, narrowed its FY26 revenue guidance, and said future collaboration R&D costs will be assigned to Roche.

News detail

Future R&D costs under the collaboration with Roche (ROP SW) will be assigned to Roche.

1 stocks
BNTXBioNTech SE American Depositary Share$89.42Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

"Iranian assessments indicate that a return to war is now the most likely scenario", Al-Arabiya reports citing sources

Geopolitics

"To my understanding, an agreement to return to the negotiating table between US and Iran is in the works", journalist Mallick reports; he adds that it's currently not 'as close' as some suggest

Geopolitics

Iranian Foreign Ministry says, following the targeting of Qeshm, that they are now in a state of war